Wegovy, Ozempic and Rybelsus: read the product before the promise

Semaglutide names can make a comparison look simpler than it is. The useful starting point is the complete product name, route and reason for treatment. A headline about the ingredient alone cannot tell you which evidence, instructions or approved use belongs to the medicine being offered. This guide concerns U.S. labeling checked in November 2026; other countries can have different authorizations.

Build a product card

Write four fields at the top of a comparison: brand, active ingredient, dosage form and intended indication. Include “tablet” or “injection” even when the brand seems familiar. Current labeling includes both routes for Wegovy, and a separate oral label covers Rybelsus and Ozempic tablets. That makes older charts equating every Ozempic product with an injection incomplete. See the Wegovy label and oral semaglutide label.

For adults considering weight management, Wegovy tablets and injection have labeled weight-management uses, with qualifying populations specified in the label. The injection also has pediatric and liver-disease indications that should not automatically be assigned to its tablets. Ozempic injection and the Rybelsus/Ozempic tablets have diabetes-related indications; their cardiovascular and kidney language must be read separately. The injection label is a distinct document.

A comparison table that stays useful

Match the claim to its document

A study and a label answer different questions. The study explains what happened under its protocol. The label defines authorized uses and product-specific safety and administration information. A provider can explain a proposed treatment outside an approved indication, but the website should identify that distinction plainly. Weight change observed during a diabetes trial does not, by itself, create a weight-management indication for every semaglutide product.

Try this test when reading an offer: could the claim be pasted onto every semaglutide page without changing a word? If so, ask for more detail. “Supports heart health” leaves several questions unanswered: which outcome, which population, which product, and what source? A good explanation lets you follow each part back to the label or original research rather than relying on brand recognition.

Bring these questions to the consultation

• Which exact product and route are being considered, and what is the treatment goal?
• Is that goal a labeled indication for this product, or a separately explained clinical use?
• Which benefits will be assessed, over what review period, and with what follow-up?
• Which pharmacy supplies the medicine, and does the quoted price identify the actual dispensed product?
• Where can I find its current Medication Guide and a direct contact for questions?

Keep the completed card with the prescription and update it whenever a refill changes the formulation or route. The aim is a comparison you can verify: one named medicine, one stated purpose and one clear explanation of how the evidence applies.